These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

524 related items for PubMed ID: 29325289

  • 1. [Optimal treatment regimen for patients with HBeAg-positive chronic hepatitis B after suboptimal response to 24 weeks of Peg-IFN α-2a].
    Luo XD, Chen XP, Chen XF.
    Zhonghua Gan Zang Bing Za Zhi; 2017 Dec 20; 25(12):896-901. PubMed ID: 29325289
    [Abstract] [Full Text] [Related]

  • 2. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
    Luo XD, Chen XF, Zhou Y, Chen XP.
    J Viral Hepat; 2017 Nov 20; 24 Suppl 1():36-42. PubMed ID: 29082651
    [Abstract] [Full Text] [Related]

  • 3. [Clinical effect of 156-week telbivudine sequential therapy in HBeAg-positive chronic hepatitis B patients with suboptimal response to pegylated interferon-α-2a therapy].
    Luo XD, Chen XP, Chen XF.
    Zhonghua Gan Zang Bing Za Zhi; 2017 Aug 20; 25(8):583-588. PubMed ID: 29056007
    [Abstract] [Full Text] [Related]

  • 4. [Efficacy of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24-week therapy with pegylated interferon-α-2a].
    Luo XD, Chen XP, Chen R, Chen XF, Huang J.
    Zhonghua Gan Zang Bing Za Zhi; 2016 Apr 20; 24(4):241-5. PubMed ID: 27470620
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study.
    Huang Z, Zhao Z, Zheng Y, Peng L, Lin C, Deng H, Gao Z.
    J Viral Hepat; 2013 Apr 20; 20 Suppl 1():52-7. PubMed ID: 23458525
    [Abstract] [Full Text] [Related]

  • 6. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W, Yuan H, Mao XR, Deng YD, Chen L.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar 20; 21(3):184-8. PubMed ID: 23967738
    [Abstract] [Full Text] [Related]

  • 7. [Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B].
    Ji YJ, Li FF, Ren WH, Zhu YH, Qin CY.
    Zhonghua Gan Zang Bing Za Zhi; 2013 May 20; 21(5):335-9. PubMed ID: 24025132
    [Abstract] [Full Text] [Related]

  • 8. [Analysis of the factors for predicting the outcomes of interferon-α and entecavir treatments for chronic hepatitis B with positive HBeAg].
    Xie Z, Zhou F, Zhou Y.
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun 20; 33(6):878-81. PubMed ID: 23803202
    [Abstract] [Full Text] [Related]

  • 9. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
    Luo X, Yu JX, Xie L, Ma WJ, Wang LH.
    Ann Hepatol; 2013 Jun 20; 16(6):888-892. PubMed ID: 29055925
    [Abstract] [Full Text] [Related]

  • 10. [HBeAg seroconversion achieved by sequential peginterferon alfa-2a therapy in chronic hepatitis B patients with unsatisfactory end point following entecavir treatment].
    Chen XF, Chen XP, Ma XJ, Chen WL, Luo XD, Liao JY.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Jul 20; 21(7):502-5. PubMed ID: 24074707
    [Abstract] [Full Text] [Related]

  • 11. [Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study].
    Zhu YY, Wu YL, Chen J, Zheng Q, Dong J, Jiang JJ.
    Zhonghua Gan Zang Bing Za Zhi; 2012 Oct 20; 20(10):737-41. PubMed ID: 23207332
    [Abstract] [Full Text] [Related]

  • 12. [Clinical effect and safety of pegylated interferon-α-2b injection (Y shape, 40 kD) in treatment of HBeAg-positive chronic hepatitis B patients].
    Hou FQ, Yin YL, Zeng LY, Shang J, Gong GZ, Pan C, Zhang MX, Yin CB, Xie Q, Peng YZ, Chen SJ, Mao Q, Chen YP, Mao QG, Zhang DZ, Han T, Wang MR, Zhao W, Liu JJ, Han Y, Zhao LF, Luo GH, Zhang JM, Peng J, Tan DM, Li ZW, Tang H, Wang H, Zhang YX, Li J, Zhang LL, Chen L, Jia JD, Chen CW, Zhen Z, Li BS, Niu JQ, Meng QH, Yuan H, Sun YT, Li SC, Sheng JF, Cheng J, Sun L, Wang GQ.
    Zhonghua Gan Zang Bing Za Zhi; 2017 Aug 20; 25(8):589-596. PubMed ID: 29056008
    [Abstract] [Full Text] [Related]

  • 13. A randomized controlled trial of sequential pegylated interferon-α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P, Lenci I, di Paolo D, Demelia L, Sorbello O, Nosotti L, Angelico M.
    Antivir Ther; 2013 Aug 20; 18(1):57-64. PubMed ID: 22872648
    [Abstract] [Full Text] [Related]

  • 14. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
    Cao ZH, Ma LN, Zhang HW, Liu YL, Chen XY.
    J Dig Dis; 2013 Aug 20; 14(8):446-50. PubMed ID: 23615131
    [Abstract] [Full Text] [Related]

  • 15. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
    Li MH, Hu LP, Zhang L, Lu Y, Shen G, Wu SL, Chang M, Mu CQ, Wu YZ, Yang M, Song SJ, Zhang SF, Hua WH, Xie Y, Cheng J, Xu DZ.
    Zhonghua Gan Zang Bing Za Zhi; 2015 Nov 20; 23(11):826-31. PubMed ID: 26743242
    [Abstract] [Full Text] [Related]

  • 16. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, Huang JF, Chen SC, Lin ZY, Yu ML, Chuang WL.
    PLoS One; 2015 Nov 20; 10(4):e0122259. PubMed ID: 25835020
    [Abstract] [Full Text] [Related]

  • 17. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.
    Dogan UB, Golge N, Akin MS.
    Eur J Gastroenterol Hepatol; 2013 Nov 20; 25(11):1312-6. PubMed ID: 23652913
    [Abstract] [Full Text] [Related]

  • 18. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z, Deng H, Zhao Q, Zheng Y, Peng L, Lin C, Zhao Z, Gao Z.
    Eur J Gastroenterol Hepatol; 2013 Oct 20; 25(10):1165-9. PubMed ID: 23571612
    [Abstract] [Full Text] [Related]

  • 19. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
    Li GJ, Yu YQ, Chen SL, Fan P, Shao LY, Chen JZ, Li CS, Yi B, Chen WC, Xie SY, Mao XN, Zou HH, Zhang WH.
    Antimicrob Agents Chemother; 2015 Jul 20; 59(7):4121-8. PubMed ID: 25941216
    [Abstract] [Full Text] [Related]

  • 20. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.
    Boglione L, Cariti G, Di Perri G, D'Avolio A.
    J Med Virol; 2016 Nov 20; 88(11):1953-9. PubMed ID: 27017932
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.